Clinical trials: IOL

Chronic Myeloproliferative Disorders, Graft Versus Host Disease

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

• Completed
• Age: Up to 45 years
• Phase 1

RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.

Conditions

Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma

Trial name

NCT00004904

Testing

anti-thymocyte globulin, filgrastim, cladribine

Where

United States

Sponsor

Northwestern University